Access practice tools, as well as industry leading news, customizable alerts, dockets, and primary content, including a comprehensive collection of case law, dockets, and regulations. Leverage...
Sept. 1 — Sen. Bernie Sanders (I-Vt.) said Sept. 1 that he will introduce legislation to stop soaring increases in prescription drug prices.
Sanders said the bill would authorize the Department of Health and Human Services to negotiate drug prices with pharmaceutical companies to bring down costs for the Medicare Part D prescription drug program.
He also said there should be tougher penalties for drug companies that commit fraud. The legislation would terminate any remaining market exclusivity period on any product found in violation of criminal or civil law through a federal fraud conviction or settlement, according to a summary of the legislation.
“We should pass legislation which says that drug companies lose their government-backed monopoly on a drug if they are found guilty of fraud in the manufacture or sale of that drug,” Sanders said.
Sanders said the bill also would ban “pay-for-delay” deals under which makers of brand-name drugs pay potential competitors to keep lower-priced generic substitutes off the market.
The bill also would require generic drug manufacturers to pay an additional rebate to Medicaid if their drug prices rise faster than inflation, mirroring the current requirements for makers of brand-name drugs, the summary said.
In addition, the bill would restore the minimum rebate on drugs covered under Medicare Part D for low-income Medicare beneficiaries, which was eliminated with the creation of Part D, according to the summary. The bill also would close the Medicare Part D doughnut hole, or coverage gap, for brand and generic drugs by 2017, three years earlier than under current law.
Sanders also said Congress should lower barriers to the importation of lower-cost drugs from other countries. He said his bill would allow individuals, pharmacists and wholesalers to import prescription drugs from licensed Canadian pharmacies.
“Americans should not have to live in fear that they will go bankrupt if they get sick,” Sanders said. “People should not have to go without the medication they need just because their elected officials aren’t willing to challenge the drug and health care industry lobby.”
Mark Merritt president of the Pharmaceutical Care Management Association, told Bloomberg BNA that it's not a good idea to have politicians determining the price of drugs because it tends to make prices go higher, not lower.
The PCMA represents pharmacy benefit managers.
The better way is to let competition work so that the drug developers that are the most competitive and offer the best discounts get the best placement on a formulary, Merritt said. “That's what's working in Medicare Part D right now,” he said.
“Price controls never work because it tends to actually lead to higher prices if you bring politics into it instead of letting market forces drive down costs,” Merritt said.
A spokeswoman from the Pharmaceutical Research and Manufacturers of America told Bloomberg BNA in an e-mail that “ensuring patients have access to the health care they need is critical. But short-sighted policies that would hinder access and slow the development of innovative medicines to help patients live longer, healthier lives is not the answer.”
“Too often, discussions about costs focus on the 10 percent of health care spending that goes toward innovative, life-saving medicines rather than looking at the big picture and ways that medicines can help avoid other unnecessary care—while ignoring how the marketplace for medicines works to hold down costs,” PhRMA's spokeswoman said. “Payers aggressively negotiate prices (including in Medicare) and use their power to incentivize use of lower cost options. Over time, medicines come off patent and face additional competition from lower-cost generics.”
To contact the reporter on this story: Bronwyn Mixter in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Brent Bierman at email@example.com
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)